Predictors of heart-focused anxiety in patients undergoing genetic investigation and counseling of long QT syndrome or hypertrophic cardiomyopathy: a one year follow-up. J Genet Counsel. 2012;21:72 84. S7.4-22. Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype- based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89:727 37. S7.4-23. Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr. 2006;19:788 95. S7.4-24. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopa- thy. N Engl J Med. 2000;342:1778 85. S7.4-25. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1481 6. S7.4-26. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardio- verter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365 73. S7.4-27. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricu- lar tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873 9. S7.4-28. Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of sys- temic blood pressure response during exercise in a community- based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044 51. S7.4-29. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assess- ment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987 91. S7.4-30. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ven- tricular tachycardia. Br Heart J. 1985;53:412 6. S7.4-31. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hyper- trophic cardiomyopathy. Heart. 2007;93:708 10. S7.4-32. Kuck KH, Kunze KP, Schluter M, et al. Programmed electrical stimu- lation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J. 1988;9:177 85. S7.4-33. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:299 302. S7.4-34. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age- dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a compre- hensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042 8. S7.4-35. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta- analysis of genotype-phenotype associations in patients with hyper- trophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99:1800 11. S7.4-36. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopa- thy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2011;124:783 831. S7.4-37. Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gado- linium enhancement in clinical outcomes for hypertrophic cardio- myopathy. JACC Cardiovasc Imaging. 2012;5:370 7. S7.4-38. O Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867 74. S7.4-39. Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast- enhanced magnetic resonance imaging in patients with hypertro- phic cardiomyopathy. Circ Heart Fail. 2010;3:51 8. S7.4-40. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratifica- tion and management. J Am Coll Cardiol. 2017;69:761 73. S7.4-41. Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127:585 93. S7.4-42. Francia P, Adduci C, Palano F, et al. Eligibility for the subcutaneous implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:893 9. CLINICAL STATEMENTS AND GUIDELINES S7.4-43. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J. 2011;32:1161 70. S7.4-44. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358:1899 908. S7.4-45. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248 57. S7.4-46. Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31:1551 3. S7.4-47. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol. 2011;107:604 8. S7.4-48. Ingles J, Doolan A, Chiu C, et al. Compound and double muta- tions in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42:e59. S7.4-49. Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753 60. S7.4-50. O Mahony C, Jichi F, Monserrat L, et al. Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricu- lar wall thickness in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2016;9:e003818. S7.4-51. Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro- physiologic testing in risk stratification for sudden cardiac death. J Invasive Cardiol. 2001;13:758 62. S7.4-52. Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one gene but many phenotypes. Am J Cardiol. 2014;113:1772 3. S7.4-53. Ho CY, Cirino AL, Lakdawala NK, et al. Evolution of hypertro- phic cardiomyopathy in sarcomere mutation carriers. Heart. 2016;102:1805 12. S7.4-54. Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardio- vascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561 7. S7.4-55. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertro- phic cardiomyopathy. Circulation. 2008;118:1541 9. S7.4-56. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of mid- ventricular obstruction in patients with hypertrophic cardiomyopa- thy. J Am Coll Cardiol. 2011;57:2346 55. S7.5-1. Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term progno- sis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J. 2002;66:133 44. S7.5-2. Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115:1733 8. S7.5-3. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860 6. S7.5-4. Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15 22. S7.5-5. Friman G, Wesslen L, Fohlman J, et al. The epidemiology of infec- tious myocarditis, lymphocytic myocarditis and dilated cardiomy- opathy. Eur Heart J. 1995:16 suppl O:36 41. S7.5-6. Hufnagel G, Pankuweit S, Richter A, et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz. 2000;25:279 85. S7.5-7. Winkel E, Parrillo J. Myocarditis. Curr Treat Options. Cardiovasc Med. 2002;4:455 66. S7.5-8. Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary case series of lupus myocarditis. Lupus. 2012;21:1378 84. S7.5-9. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowl- edge on aetiology, diagnosis, management, and therapy of myo- carditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636 2648d. S7.5-10. Elamm C, Fairweather D, Cooper LT, Pathogenesis and diagnosis of myocarditis. Heart. 2012;98:835 40. S7.5-11. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738 47. S7.5-12. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term out- come of fulminant myocarditis as compared with acute (nonfulmi- nant) myocarditis. N Engl J Med. 2000;342:690 5. S7.5-13. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091 100. S7.5-14. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639 48. S7.5-15. Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia asso- ciated with Coxsackie B4 virus infection. Acta Paediatr Scand. 1990;79:572 5. S7.5-16. Tai YT, Lau CP, Fong PC, et al. Incessant automatic ventricular tachy- cardia complicating acute coxsackie B myocarditis. Cardiology. 1992;80:339 44. S7.5-17. Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, ventricular arrhythmias with reversible prolonged Q-Tc interval in typhoid myocarditis. J Indian Med Assoc. 1987;85:336 7. S7.5-18. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803 69. S7.5-19. Cooper LT Jr, Elamm C, Giant cell myocarditis. Diagnosis and treat- ment. Herz. 2012;37:632 6. S7.5-20. Milei J, Grana D, Fernandez AG, et al. Cardiac involvement in acquired immunodeficiency syndrome a review to push action. The Committee for the Study of Cardiac Involvement in AIDS. Clin Cardiol. 1998;21:465 72. S7.5-21. Yunis NA, Stone VE, Cardiac manifestations of HIV/AIDS: a review of disease spectrum and clinical management. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:145 54. S7.5-22. Huang CN, Yu HH, Chiu SN, et al. Acute myocarditis and ventricular fibrillation as initial presentation of pediatric systemic lupus erythe- matosus. Rheumatol Int. 2013;33:1093 6. S7.5-23. Rassi A Jr, Rassi A, Little WC, Chagas heart disease. Clin Cardiol. 2000;23:883 9. S7.5-24. Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter defibrillators in patients with Chagas disease: are they different from patients with coronary disease? Pacing Clin Electrophysiol. 1997;20:194 7. S7.5-25. d Avila A, Splinter R, Svenson RH, et al. New perspectives on cath- eter-based ablation of ventricular tachycardia complicating Chagas disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas VT. J Interv Card Electrophysiol. 2002;7:23 38. S7.5-26. Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.5-27. Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol. 2004;27:4 9. S7.5-28. Cooper LT, Okura Y. Idiopathic giant cell myocarditis. Curr Treat Options Cardiovasc Med. 2001;3:463 7. 7.6. Cardiac Sarcoidosis S7.6-1. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epi- demiology, characteristics, and outcome over 25 years in a nation- wide study. Circulation. 2015;131:624 32. S7.6-2. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long- term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006 10. S7.6-3. Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implant- able cardiac defibrillators for treatment of ventricular arrhyth- mias in patients with cardiac sarcoidosis. Europace. 2013;15: 347 54. CLINICAL STATEMENTS AND GUIDELINES S7.6-4. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electro- physiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2014;25:171 6. S7.6-5. Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defi- brillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925 9. S7.6-6. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016;10:411 20. S7.6-7. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial dam- age in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738. S7.6-8. Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imag- ing for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhyth- mias. Circ Arrhythm Electrophysiol. 2014;7:1109 15. S7.6-9. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501 11. S7.6-10. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with sus- pected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329 36. S7.6-11. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ven- tricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276 82. S7.6-12. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779 89. S7.6-13. Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of car- diac sarcoidosis. Am J Cardiol. 2015;115:505 9. S7.6-14. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407 13. S7.6-15. Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9:e003353. S7.6-16. Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:140 7. S7.6-17. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus state- ment on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305 23. S7.6-18. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sud- den cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43 8. 7.6.1. Other Infiltrative Cardiomyopathies S7.6.1-1. Lubitz SA, Goldbarg SH, Mehta D, Sudden cardiac death in infiltra- tive cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hema- chromatosis. Prog Cardiovasc Dis. 2008;51:58 73. S7.6.1-2. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implanta- tion of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235 40. S7.6.1-3. Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemother- apy for light-chain amyloidosis in patients presenting with symp- tomatic heart failure. J Am Coll Cardiol. 2016;67:2941 8. S7.6.1-4. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter- defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11:158 62. 7.7. Heart Failure 7.7.1. HF With Reduced Ejection Fraction S7.7.1-1. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158 65. S7.7.1-2. Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.7.1-3. Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrilla- tor as a bridge to cardiac transplantation: a national database analy- sis. J Heart Lung Transplant. 2015;34:1305 49. S7.7.1-4. Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation. 2001;104:171 6. S7.7.1-5. Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardio- verter-defibrillators on waitlist mortality among patients await- ing heart transplantation. An UNOS/OPTN Analysis. JACC Clin Electrophysiol. 2017;3:33 40. S7.7.1-6. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170 6. S7.7.1-7. MERIT-HF Study Effect of metoprolol CR/XL in chronic heart fail- ure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001 7. S7.7.1-8. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675 80. S7.7.1-9. Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classifica- tion. Eur Heart J. 1996;17:1390 403. S7.7.1-10. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients characteristics: a meta-analysis of clinical tri- als. Arch Intern Med. 2000;160:621 7. S7.7.1-11. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldoste- rone blocker, in patients with left ventricular dysfunction after myo- cardial infarction. N Engl J Med. 2003;348:1309 21. S7.7.1-12. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin- receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990 7. S7.7.1-13. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539 4. S7.7.1-14. Tomaselli GF, Zipes DP, What causes sudden death in heart failure? Circ Res. 2004;95:754 63. S7.7.1-15. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;97:155 60. S7.7.1-16. Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic and metabolic remodelling of failing human heart. J Physiol. 2016;594:3963 80. S7.7.1-17. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter- defibrillator use in patients with left ventricular assist devices: a sys- tematic review and meta-analysis. JACC Heart Fail. 2016;4:772 9. 7.7.2. HF With Preserved Ejection Fraction S7.7.2-1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251 9. S7.7.2-2. Adabag S, Smith LG, Anand IS, et al. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012;18:749 54. S7.7.2-3. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. S7.7.2-4. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesar- tan in patients with chronic heart failure and preserved left- ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. S7.7.2-5. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370: 1383 92. S7.7.2-6. Al-Khatib SM, Shaw LK, O Connor C, et al. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231 5. S7.7.2-7. Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac- tion in tetralogy of Fallot. QRS prolongation relates to right ventricu- lar size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231 7. CLINICAL STATEMENTS AND GUIDELINES S7.7.2-8. Gatzoulis KA, Tsiachris D, Arsenos P, et al. Prognostic value of pro- grammed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol. 2014;176:1449 51. 7.7.3. Left Ventricular Assist Device S7.7.3-1. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter- defibrillator use in patients with left ventricular assist devices: a sys- tematic review and meta-analysis. JACC Heart Fail. 2016;4:772 9. S7.7.3-2. Cantillon DJ, Tarakji KG, Kumbhani DJ, et al. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator. Heart Rhythm. 2010;7:466 71. S7.7.3-3. Raasch H, Jensen BC, Chang PP, et al. Epidemiology, management, and outcomes of sustained ventricular arrhythmias after contin- uous-flow left ventricular assist device implantation. Am Heart J. 2012;164:373 8. S7.7.3-4. Garan AR, Yuzefpolskaya M, Colombo PC, et al. Ventricular arrhyth- mias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol. 2013;61:2542 50. S7.7.3-5. Refaat MM, Tanaka T, Kormos RL, et al. Survival benefit of implant- able cardioverter-defibrillators in left ventricular assist device-sup- ported heart failure patients. J Card Fail. 2012;18:140 5. S7.7.3-6. Enriquez AD, Calenda B, Miller MA, et al. The role of implantable cardioverter-defibrillators in patients with continuous flow left ven- tricular assist devices. Circ Arrhythm Electrophysiol. 2013;6:668 74. S7.7.3-7. Lee W, Tay A, Subbiah RN, et al. Impact of implantable cardioverter defibrillators on survival of patients with centrifugal left ventricular assist devices. Pacing Clin Electrophysiol. 2015;38:925 33. S7.7.3-8. Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destina- tion therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospec- tive study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751 7. S7.7.3-9. Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ven- tricular assist devices: patient selection and outcomes. Curr Opin Cardiol. 2011;26:232 6. 7.7.4. ICD Use After Heart Transplantation S7.7.4-1. Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable car- dioverter-defibrillators in heart transplant recipients: results from a multicenter registry. Circ Heart Fail. 2009;2:197 201. S7.7.4-2. McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac resynchronization therapy in heart transplant recipients: results of a national survey. J Heart Lung Transplant. 2009;28:847 50. S7.7.4-3. Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defi- brillators in a heart transplant population: A single-center experi- ence. J Heart Lung Transplant. 2016;35:682 4. S7.7.4-4. Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and tem- poral trends of sudden cardiac death after heart transplantation. Heart Rhythm. 2014;11:1684 90. S7.7.4-5. Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm. 2009;6:503 9. 7.8. Neuromuscular Disorders S7.8-1. Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ven- tricular systolic dysfunction and heart failure in adults with myotonic dystrophy type 1. Am Heart J. 2010;160:1137 41, 41. S7.8-2. Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implica- tions for catheter ablation. Circulation. 1998;98:541 6. S7.8-3. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. S7.8-4. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll Cardiol. 2012;59:493 500. S7.8-5. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud- den death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209 10. S7.8-6. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250 60. S7.8-7. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79 83. S7.8-8. Russo V, Nigro G. ICD role in preventing sudden cardiac death in Emery-Dreifuss muscular dystrophy with preserved myocardial func- tion: 2013 ESC guidelines on cardiac pacing and cardiac resynchro- nization therapy. Europace. 2015;17:337. S7.8-9. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormali- ties and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688 97. S7.8-10. Lallemand B, Clementy N, Bernard-Brunet A, et al. The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications. Heart. 2012;98:291 6. S7.8-11. Nazarian S, Wagner KR, Caffo BS, et al. Clinical predictors of con- duction disease progression in type I myotonic muscular dystrophy. Pacing Clin Electrophysiol. 2011;34:171 6. S7.8-12. Tanawuttiwat T, Wagner KR, Tomaselli G, et al. Left ventricular dys- function and conduction disturbances in patients with myotonic muscular dystrophy type I and II. JAMA Cardiology. 2017;2:225 8. S7.8-13. Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardio- verter-defibrillator use in a US myotonic dystrophy type 1 popula- tion. J Cardiovasc Electrophysiol. 2011;22:1369 75. S7.8-14. Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol. 2011;150:54 8. S7.8-15. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890 5. S7.8-16. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormali- ties: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350 408. S7.8-17. Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhyth- mic and nonarrhythmic outcomes of lamin A/C mutation carriers. Circulation. 2008;117:e350 408. S7.8-18. Brembilla-Perrot B, Luporsi JD, Louis S, et al. Long-term follow-up of patients with myotonic dystrophy: an electrocardiogram every year is not necessary. Europace. 2011;13:251 7. S7.8-19. Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio- ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II Pacing. Clin Electrophysiol. 2012;35:1262 9. 7.9. Cardiac Channelopathies S7.9-1. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6 15. S7.9-2. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syn- drome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S7.9-3. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher- ited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. S7.9-4. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37 45. S7.9-5. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 74. S7.9-6. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016;134:872 82. CLINICAL STATEMENTS AND GUIDELINES S7.9-7. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. S7.9-8. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616 23. S7.9-9. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003;14:337 41. S7.9-10. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defi- brillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005;2:497 504. S7.9-11. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426 34. S7.9-12. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577 83. S7.9-13. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010;121:635 43. S7.9-14. Delise P, Allocca G, Marras E, et al. Risk stratification in individu- als with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011;32:169 76. S7.9-15. Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk strati- fication of young adults with Brugada syndrome. J Electrocardiol. 2013;46:279 83. S7.9-16. Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm. 2008;5:831 6. S7.9-17. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation. 2001;104:557 62. S7.9-18. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342 7. S7.9-19. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syn- drome. JAMA. 2006;296:1249 54. S7.9-20. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta- blockers. JAMA. 2004;292:1341 4. S7.9-21. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S7.9-22. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol. 2009;54:832 7. S7.9-23. Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016. S7.9-24. Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60000 exomes and ACMG guidelines question the role of catecholamin- ergic polymorphic ventricular tachycardia-associated variants. Clin Genet. 2017;91:63 72. S7.9-25. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587 95. S7.9-26. Mahida S, Derval N, Sacher F, et al. Role of electrophysiological stud- ies in predicting risk of ventricular arrhythmia in early repolarization syndrome. J Am Coll Cardiol. 2015;65:151 9. S7.9-27. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natu- ral history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300 8. S7.9-28. Siebermair J, Sinner MF, Beckmann BM, et al. Early repolarization pat- tern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace. 2016;18:718 25. S7.9-29. Etheridge SP, Sanatani S, Cohen MI, et al. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol. 2007;50:1335 40. S7.9-30. Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-cen- ter experience. Heart Rhythm. 2010;7:1616 22. S7.9-31. Proclemer A, Ghidina M, Facchin D, et al. Use of implantable cardio- verter-defibrillator in inherited arrhythmogenic diseases: data from Italian ICD Registry for the years 2001 6. Pacing Clin Electrophysiol. 2009;32:434 45. S7.9-32. Adler A, Sadek MM, Chan AY, et al. Patient outcomes from a spe- cialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. 2016;9:e003440. S7.9-33. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defi- brillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879 88. S7.9-34. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13:443 54. S7.9-35. Rodriguez-Manero M, Sacher F, de Asmundis C, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13:669 82. S7.9-36. Rosso R, Glick A, Glikson M, et al. Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J. 2008;10:435 9. S7.9-37. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9-38. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-adren- ergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830 7. S7.9-39. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 1991;84:1524 9. S7.9-40. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta- blockers in long-QT syndrome type 1: contribution of noncompli- ance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures. Circulation. 2009;119:215 21. 7.9.1. Specific Cardiac Channelopathy Syndromes 7.9.1.1. Congenital Long QT Syndrome S7.9.1.1-1. Abu-Zeitone A, Peterson DR, Polonsky B, et al. Efficacy of differ- ent beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014;64:1352 8. S7.9.1.1-2. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol. 2010;21:893 901. S7.9.1.1-3. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limita- tions of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616 23. S7.9.1.1-4. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329 37. S7.9.1.1-5. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta- blockers in long-QT syndrome type 1: contribution of noncompli- ance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures. Circulation. 2009;119:215 21. S7.9.1.1-6. Chorin E, Hu D, Antzelevitch C, et al. Ranolazine for congeni- tal long-qt syndrome type III: experimental and long-term clinical data. Circ Arrhythm Electrophysiol. 2016;9:e004370. S7.9.1.1-7. Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in type 3 long QT syndrome. Europace. 2017 euw439 [Epub ahead of print]. S7.9.1.1-8. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA. 2006;296:1249 54. S7.9.1.1-9. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55:783 8. S7.9.1.1-10. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053 8. S7.9.1.1-11. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183 9. S7.9.1.1-12. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolonga- tion and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr. 2009;168:1107 15. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.1-13. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and cate- cholaminergic polymorphic ventricular tachycardia using video- assisted thoracic surgery. Heart Rhythm. 2009;6:752 9. S7.9.1.1-14. Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life- threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404 9. S7.9.1.1-15. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym- pathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catechol- aminergic polymorphic ventricular tachycardia and long QT syn- drome. Clin Res Cardiol. 2013;102:33 42. S7.9.1.1-16. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826 33. S7.9.1.1-17. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6 15. S7.9.1.1-18. Costa J, Lopes CM, Barsheshet A, et al. Combined assessment of sex- and mutation-specific information for risk stratification in type 1 long QT syndrome. Heart Rhythm. 2012;9:892 8. S7.9.1.1-19. Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm. 2010;7:1797 805. S7.9.1.1-20. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender- specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. Heart Rhythm. 2011;8:1537 43. S7.9.1.1-21. Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol. 2006;47:764 8. S7.9.1.1-22. Adler A, van der Werf C, Postema PG, et al. The phenomenon of QT stunning : The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9:901 8. S7.9.1.1-23. Aziz PF, Wieand TS, Ganley J, et al. Genotype- and mutation site-specific QT adaptation during exercise, recovery, and pos- tural changes in children with long-QT syndrome. Circ Arrhythm Electrophysiol. 2011;4:867 73. S7.9.1.1-24. Chattha IS, Sy RW, Yee R, et al. Utility of the recovery electrocar- diogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? Heart Rhythm. 2010;7:906 11. S7.9.1.1-25. Laksman ZW, Hamilton RM, Chockalingam P, et al. Mutation loca- tion effect on severity of phenotype during exercise testing in type 1 long-QT syndrome: impact of transmembrane and C-loop loca- tion. J Cardiovasc Electrophysiol. 2013;24:1015 20. S7.9.1.1-26. Moltedo JM, Kim JJ, Friedman RA, et al. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr Cardiol. 2011;32:63 6. S7.9.1.1-27. Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187 94. S7.9.1.1-28. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syn- drome. Eur Heart J. 2004;25:1405 11. S7.9.1.1-29. Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bed- side test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955 61. S7.9.1.1-30. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341 4. S7.9.1.1-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S7.9.1.1-32. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149 54. S7.9.1.1-33. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syn- drome. Pharmacol Rev. 2010;62:760 81. S7.9.1.1-34. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and therapy for attention deficit/hyperactivity disorder. J Cardiovasc Electrophysiol. 2015;26:1039 44. S7.9.1.1-35. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. S7.9.1.1-36. Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 long-QT syndrome: an international multicenter study. Circulation. 2016;134:872 82. S7.9.1.1-37. Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm. 2009;6:113 20. S7.9.1.1-38. Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866 72. S7.9.1.1-39. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recom- mendations for the use of automated external defibrillators (AEDs) in Europe. Eur Heart J. 2004;25:437 45. S7.9.1.1-40. Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol. 2016;47:163 70. S7.9.1.1-41. Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-block- ers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60:2092 9. S7.9.1.1-42. Khositseth A, Tester DJ, Will ML, et al. Identification of a com- mon genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1: 60 4. S7.9.1.1-43. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syn- drome. LQTS Investigators. Circulation. 1998;97:451 6. S7.9.1.1-44. Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9.1.1-45. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta- adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830 7. S7.9.1.1-46. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. CIRCULATION. 1991;84:1524 9. S7.9.1.1-47. Viskin S, Glikson M, Fish R, et al. Rate smoothing with car- diac pacing for preventing torsade de pointes. Am J Cardiol. 2000;86:111k 5k. S7.9.1.1-48. Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonre- sponders. Circ Arrhythm Electrophysiol. 2013;6:705 11. S7.9.1.1-49. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachy- cardia. N Engl J Med. 2008;358:2024 9. S7.9.1.1-50. Li J, Liu Y, Yang F, et al. Video-assisted thoracoscopic left car- diac sympathetic denervation: a reliable minimally invasive approach for congenital long-QT syndrome. Ann Thorac Surg. 2008;86:1955 8. S7.9.1.1-51. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical manage- ment of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation. 2015;131:2185 93. S7.9.1.1-52. Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic dener- vation for long QT syndrome: effects on QT interval and heart rate. Heart Vessels. 2005;20:137 41. S7.9.1.1-53. Burns C, Ingles J, Davis AM, et al. Clinical and genetic features of Australian families with long QT syndrome: a registry based study. J Arrhythm. 2016;32:456 61. S7.9.1.1-54. Barsheshet A, Goldenberg I, Uchi J, et al. Mutations in cyto- plasmic loops of the KCNQ1 channel and the risk of life-threat- ening events: implications for mutation-specific response to beta-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125:1988 96. S7.9.1.1-55. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clini- cal manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366 75. S7.9.1.1-56. Zhang C, Kutyifa V, McNitt S, et al. Identification of low-risk adult congenital LQTS patients. J Cardiovasc Electrophysiol. 2015;26:853 8. S7.9.1.1-57. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharma- cological treatment. J Am Coll Cardiol. 2004;43:1494 9. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.1-58. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol. 2009;54:832 7. S7.9.1.1-59. Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016. S7.9.1.1-60. Rohatgi RK, Bos JM, Ackerman MJ. Stimulant therapy in chil- dren with attention-deficit/hyperactivity disorder and concomi- tant long QT syndrome: a safe combination? Heart Rhythm. 2015;12:1807 12. S7.9.1.1-61. Amin AS, Klemens CA, Verkerk AO, et al. Fever-triggered ven- tricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J. 2010;18:165 9. S7.9.1.1-62. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013 22. 7.9.1.2. Catecholaminergic Polymorphic Ventricular Tachycardia S7.9.1.2-1. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricu- lar tachycardia. Circulation. 2009;119:2426 34. S7.9.1.2-2. Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of thera- peutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015;8:633 42. S7.9.1.2-3. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic denervation for the treatment of long QT syndrome and cate- cholaminergic polymorphic ventricular tachycardia using video- assisted thoracic surgery. Heart Rhythm. 2009;6:752 9. S7.9.1.2-4. Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic sympathectomy for cardiac denervation in patients with life- threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. 2014;147:404 9. S7.9.1.2-5. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym- pathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catechol- aminergic polymorphic ventricular tachycardia and long QT syn- drome. Clin Res Cardiol. 2013;102:33 42. S7.9.1.2-6. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244 5. S7.9.1.2-7. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69 74. S7.9.1.2-8. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymor- phic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512 9. S7.9.1.2-9. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel block- ers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:1149 54. S7.9.1.2-10. Swan H, Laitinen P, Kontula K, et al. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catechol- aminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol. 2005;16:162 6. S7.9.1.2-11. Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recur- rences in genotype-negative patients with catecholaminergic poly- morphic ventricular tachycardia. Heart Rhythm. 2013;10:542 7. S7.9.1.2-12. Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhyth- mic drugs in catecholaminergic polymorphic ventricular tachycar- dia. Circ Arrhythm Electrophysiol. 2011;4:128 35. S7.9.1.2-13. Adler A, Sadek MM, Chan AY, et al. Patient outcomes from a spe- cialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. 2016;9:e003440. S7.9.1.2-14. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13:443 54. S7.9.1.2-15. Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defi- brillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11:58 66. S7.9.1.2-16. Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ven- tricular tachycardia. Heart Rhythm. 2011;8:864 71. S7.9.1.2-17. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical manage- ment of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation. 2015;131:2185 93. S7.9.1.2-18. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachy- cardia. N Engl J Med. 2008;358:2024 9. S7.9.1.2-19. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and therapy for attention deficit/hyperactivity disorder. J Cardiovasc Electrophysiol. 2015;26:1039 44. S7.9.1.2-20. Jabbari J, Jabbari R, Nielsen MW, et al. New exome data ques- tion the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia. Circ Cardiovasc Genetics. 2013;6:481 9. S7.9.1.2-21. Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation. 2013;127:1009 17. S7.9.1.2-22. Makita N, Yagihara N, Crotti L, et al. Novel calmodulin muta- tions associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet. 2014;7:466 74. S7.9.1.2-23. Marsman RF, Barc J, Beekman L, et al. A mutation in CALM1 encoding calmodulin in familial idiopathic ventricular fibrilla- tion in childhood and adolescence. J Am Coll Cardiol. 2014;63: 259 66. S7.9.1.2-24. Nyegaard M, Overgaard MT, Sondergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet. 2012;91:703 12. S7.9.1.2-25. Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60000 exomes and acmg guidelines question the role of cat- echolaminergic polymorphic ventricular tachycardia-associated variants. Clin Genet. 2017;91:63 72. 7.9.1.3. Brugada Syndrome S7.9.1.3-1. Casado-Arroyo R, Berne P, Rao JY, et al. Long-term trends in newly diagnosed Brugada syndrome: implications for risk stratification. J Am Coll Cardiol. 2016;68:614 23. S7.9.1.3-2. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of indi- viduals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577 83. S7.9.1.3-3. Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk strati- fication of young adults with Brugada syndrome. J Electrocardiol. 2013;46:279 83. S7.9.1.3-4. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37 45. S7.9.1.3-5. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010;121: 635 43. S7.9.1.3-6. Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation. 2016;133:622 30. S7.9.1.3-7. Belhassen B, Rahkovich M, Michowitz Y, et al. Management of Brugada syndrome: thirty-three-year experience using elec- trophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol. 2015;8:1393 402. S7.9.1.3-8. Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phe- notype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol. 2015;8:1373 81. S7.9.1.3-9. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by cath- eter ablation over the anterior right ventricular outflow tract epi- cardium. Circulation. 2011;123:1270 9. S7.9.1.3-10. Sunsaneewitayakul B, Yao Y, Thamaree S, et al. Endocardial mapping and catheter ablation for ventricular fibrillation preven- tion in Brugada syndrome. J Cardiovasc Electrophysiol. 2012;23 suppl 1:S10 6. S7.9.1.3-11. Zhang P, Tung R, Zhang Z, et al. Characterization of the epicar- dial substrate for catheter ablation of Brugada syndrome. Heart Rhythm. 2016;13:2151 8. CLINICAL STATEMENTS AND GUIDELINES S7.9.1.3-12. Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Europace. 2017;19:665 94. S7.9.1.3-13. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J. 2011;32:169 76. S7.9.1.3-14. Somani R, Krahn AD, Healey JS, et al. Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER). Heart Rhythm. 2014;11:1047 54. S7.9.1.3-15. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for the 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e392 e414. S7.9.1.3-16. Sieira J, Ciconte G, Conte G, et al. Asymptomatic Brugada syn- drome: clinical characterization and long-term prognosis. Circ Arrhythm Electrophysiol. 2015;8:1144 50. S7.9.1.3-17. Sieira J, Conte G, Ciconte G, et al. Prognostic value of pro- grammed electrical stimulation in Brugada syndrome: 20 years experience. Circ Arrhythm Electrophysiol. 2015;8: 777 84. S7.9.1.3-18. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of mutations involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol. 2012;60:1410 8. S7.9.1.3-19. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syn- drome. Circ Cardiovasc Genet. 2009;2:552 7. S7.9.1.3-20. Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of genetic variants previously associated with Brugada syndrome in new exome data. Clinical Genetics. 2013;84:489 95. S7.9.1.3-21. Brugada drugs. Available at: http://www.brugadadrugs.org. Accessed October 6, 2016. S7.9.1.3-22. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syn- drome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335 41. S7.9.1.3-23. Andorin A, Behr ER, Denjoy I, et al. Impact of clinical and genetic findings on the management of young patients with Brugada syn- drome. Heart Rhythm. 2016;13:1274 82. S7.9.1.3-24. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con- sensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932 63. S7.9.1.3-25. McNamara DA, Goldberger JJ, Berendsen MA, et al. Implantable defibrillators versus medical therapy for cardiac channelopathies. Cochrane Database Syst Rev. 2015;CD011168. S7.9.1.3-26. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for unexplained death in Thailand (DEBUT): a ran- domized clinical trial. Circulation. 2003;107:2221 6. S7.9.1.3-27. Rodriguez-Manero M, Sacher F, de AC, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13: 669 82. S7.9.1.3-28. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510 5. S7.9.1.3-29. Shimeno K, Takagi M, Maeda K, et al. Usefulness of multichannel Holter ECG recording in the third intercostal space for detecting type 1 Brugada ECG: comparison with repeated 12-lead ECGs. J Cardiovasc Electrophysiol. 2009;20:1026 31. S7.9.1.3-30. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defi- brillator therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll Cardiol. 2015;65:879 88. S7.9.1.3-31. Kapplinger JD, Tester DJ, Alders M, et al. An international com- pendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic test- ing. Heart Rhythm. 2010;7:33 46. S7.9.1.3-32. Adler A, Rosso R, Chorin E, et al. Risk stratification in Brugada syn- drome: clinical characteristics, electrocardiographic parameters, and auxiliary testing. Heart Rhythm. 2016;13:299 310. S7.9.1.3-33. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and manage- ment. Circulation. 2002;105:1342 7. 7.9.1.4. Early Repolarization J-wave Syndrome S7.9.1.4-1. Rosso R, Kogan E, Belhassen B, et al. J-point elevation in sur- vivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol. 2008;52:1231 8. S7.9.1.4-2. Adhikarla C, Boga M, Wood AD, et al. Natural history of the electrocardiographic pattern of early repolarization in ambulatory patients. Am J Cardiol. 2011;108:1831 5. S7.9.1.4-3. Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol. 2009;53:612 9. S7.9.1.4-4. Siebermair J, Sinner MF, Beckmann BM, et al. Early repolariza- tion pattern is the strongest predictor of arrhythmia recurrence in patients with idiopathic ventricular fibrillation: results from a single centre long-term follow-up over 20 years. Europace. 2016;18:718 25. S7.9.1.4-5. Sinner MF, Porthan K, Noseworthy PA, et al. A meta-analysis of genome-wide association studies of the electrocardio- graphic early repolarization pattern. Heart Rhythm. 2012;9: 1627 34. S7.9.1.4-6. Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med. 2009;361:2529 37. S7.9.1.4-7. Tikkanen JT, Wichmann V, Junttila MJ, et al. Association of early repolarization and sudden cardiac death during an acute coronary event. Circ Arrhythm Electrophysiol. 2012;5:714 8. S7.9.1.4-8. Junttila MJ, Tikkanen JT, Kentta T, et al. Early repolarization as a predictor of arrhythmic and nonarrhythmic cardiac events in middle-aged subjects. Heart Rhythm. 2014;11:1701 6. S7.9.1.4-9. Cheng YJ, Lin XX, Ji CC, et al. Role of early repolarization pat- tern in increasing risk of death. J Am Heart Assoc. 2016;5: e003375. 7.9.1.5. Short QT Syndrome S7.9.1.5-1. Dhutia H, Malhotra A, Parpia S, et al. The prevalence and signifi- cance of a short QT interval in 18825 low-risk individuals includ- ing athletes. Br J Sports Med. 2016;50:124 9. S7.9.1.5-2. Gollob MH, Redpath CJRoberts JD, The short QT syndrome: pro- posed diagnostic criteria. J Am Coll Cardiol. 2011;57:802 1. S7.9.1.5-3. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow- up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587 95. S7.9.1.5-4. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300 8. S7.9.1.5-5. Villafane J, Atallah J, Gollob MH, et al. Long-term follow-up of a pediatric cohort with short QT syndrome. J Am Coll Cardiol. 2013;61:1183 91. S7.9.1.5-6. Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clini- cal findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440 7. S7.9.1.5-7. Bun SS, Maury P, Giustetto C, et al. Electrical storm in short-QT syndrome successfully treated with isoproterenol. J Cardiovasc Electrophysiol. 2012;23:1028 30. S7.9.1.5-8. Guerrier K, Kwiatkowski D, Czosek RJ, et al. Short QT interval prevalence and clinical outcomes in a pediatric population. Circ Arrhythm Electrophysiol. 2015;8:1460 4. S7.9.1.5-9. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of 1.7 million persons: prevalence, correlates, and prognosis. Ann Noninvasive Electrocardiol. 2014;19:490 500. S7.9.1.5-10. Gollob MH, Blier L, Brugada R, et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited car- diac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint posi- tion paper. Can J Cardiol. 2011;27:232 458. CLINICAL STATEMENTS AND GUIDELINES 8. VA IN THE STRUCTURALLY NORMAL HEART S8-1. Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J. 1993;126:1126 33. S8-2. Gill JS, Ward DE, Camm AJ, Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15:2122 6. S8-3. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta blocker therapy: results from the American College of Cardiology s NCDR(R). Am Heart J. 2011;161:864 70. S8-4. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amioda- rone for recurrent sustained hypotensive ventricular tachyarrhyth- mias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol. 1996;27:67 75. S8-5. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initi- ated by premature extrasystoles originating from the right ventricu- lar outflow tract. J Am Coll Cardiol. 2005;46:1288 94. S8-6. Viskin S, Idiopathic polymorphic ventricular tachycardia: a benign disease with a touch of bad luck? Korean Circ J. 2017;47: 299 306. S8-7. Viskin S, Rosso R, Rogowski O, et al. The short-coupled variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 2005;16:912 6. S8-8. Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of ateno- lol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144:e10. S8-9. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth- mic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237 43. S8-10. Hohnloser SH, Meinertz T, Stubbs P, et al. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. Circulation. 1995;92:1517 25. S8-11. Badhwar N, Scheinman MM, Idiopathic ventricular tachycardia: diagnosis and management. Curr Probl Cardiol. 2007;32:7 43. S8-12. Connolly SJ, Meta-analysis of antiarrhythmic drug trials. Am J Cardiol. 1999;84:90R 3. S8.1-1. Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricu- lar arrhythmias. J Am Coll Cardiol. 2005;45:877 86. 8.1. Outflow Tract and Atrioventricular Annular VA S8.1-2. Yamada T, Litovsky SH, Kay GN, The left ventricular ostium: an ana- tomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2008;1:396 404. S8.1-3. Yamada T, Maddox WR, McElderry HT, et al. Radiofrequency cath- eter ablation of idiopathic ventricular arrhythmias originating from intramural foci in the left ventricular outflow tract: efficacy of sequential versus simultaneous unipolar catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:344 52. S8.1-4. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth- mic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7:237 43. S8.1-5. Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular prema- ture depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced car- diomyopathy. Heart Rhythm. 2014;11:299 306. S8.1-6. Kamioka M, Mathew S, Lin T, et al. Electrophysiological and electro- cardiographic predictors of ventricular arrhythmias originating from the left ventricular outflow tract within and below the coronary sinus cusps. Clin Res Cardiol. 2015;104:544 54. S8.1-7. Konstantinidou M, Koektuerk B, Wissner E, et al. Catheter ablation of right ventricular outflow tract tachycardia: a simplified remote- controlled approach. Europace. 2011;13:696 700. S8.1-8. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter out- comes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1:116 23. S8.1-9. Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias origi- nating from the pulmonary sinus cusp: prevalence, electrocardio- graphic/electrophysiological characteristics, and catheter ablation. J Am Coll Cardiol. 2015;66:2633 44. S8.1-10. Morady F, Kadish AH, DiCarlo L, et al. Long-term results of cath- eter ablation of idiopathic right ventricular tachycardia. Circulation. 1990;82:2093 9. S8.1-11. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardio- graphic characterization for guiding catheter ablation. J Am Coll Cardiol. 2002;39:500 8. S8.1-12. Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014;11: e166 96. S8.1-13. Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhyth- mias arising from the pulmonary artery: prevalence, character- istics, and topography of the arrhythmia origin. Heart Rhythm. 2008;5:419 26. S8.1-14. Yamada T, McElderry HT, Doppalapudi H, et al. 